Latest news with #PlusTherapeutics
Business Insider
3 days ago
- Business
- Business Insider
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year
The company recognized $1.1M in grant revenue in the first quarter of 2025 compared to $1.7M in in the first quarter of 2024, which represents CPRIT's share of the costs incurred for the REYOBIQ platform advancement for the treatment of patients with LM. 'We improved our cash position in the first quarter as a result of both a financing and grant support,' said Marc Hedrick, M.D., Plus Therapeutics (PSTV) President and Chief Executive Officer. 'With the additional cash and further anticipated grant support in 2025, we are well positioned to make solid progress in our 2 key business goals: enrollment in our REYOBIQ CNS cancer radiotherapeutic clinical trials and the planned launch of the CNSide cerebral spinal fluid assay platform.' Confident Investing Starts Here:
Yahoo
3 days ago
- Business
- Yahoo
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -229.41%. A quarter ago, it was expected that this developer of cell therapies would post a loss of $0.51 per share when it actually produced a loss of $0.67, delivering a surprise of -31.37%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Plus , which belongs to the Zacks Medical - Drugs industry, posted revenues of $1.06 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 42.76%. This compares to year-ago revenues of $1.68 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Plus shares have lost about 75.1% since the beginning of the year versus the S&P 500's gain of 0.5%. While Plus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Plus: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.17 on $1.9 million in revenues for the coming quarter and -$0.67 on $8.23 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, IGC Pharma, Inc. (IGC), has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. IGC Pharma, Inc.'s revenues are expected to be $0.31 million, up 6.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Plus Therapeutics, Inc. (PSTV) : Free Stock Analysis Report IGC Pharma, Inc. (IGC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Business
- Yahoo
Plus: Q1 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Plus Therapeutics, Inc. (PSTV) on Friday reported a loss of $17.4 million in its first quarter. The Houston-based company said it had a loss of $1.19 per share. Losses, adjusted for non-recurring costs, came to 56 cents per share. The developer of cell therapies posted revenue of $1.1 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on PSTV at Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Plus: Q1 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Plus Therapeutics, Inc. (PSTV) on Friday reported a loss of $17.4 million in its first quarter. The Houston-based company said it had a loss of $1.19 per share. Losses, adjusted for non-recurring costs, came to 56 cents per share. The developer of cell therapies posted revenue of $1.1 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on PSTV at Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the 'Company') today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the 'Quarterly Report'). The Nasdaq Listing Rule requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the 'SEC'). This notification has no immediate effect on the listing of the Company's securities on Nasdaq. Nasdaq has informed the Company that it must submit a plan to regain compliance with respect to the filing requirement by July 21, 2025. If the plan is accepted, Nasdaq can grant an exception of up to 180 calendar dates from the due date of the filing, or until November 17, 2025, to regain compliance. The Company is working diligently to file the Quarterly Report as promptly as practical, and expects to return to a normal filing cadence for the remainder of 2025. About Plus Therapeutics Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based upon current expectations or beliefs, as well as assumptions about future events. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as 'expect,' 'plan,' or 'potential,' or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements relating to the Company's plans and expectations about the completion and filing of the Quarterly Report on Form 10-Q for the period ended March 31, 2025, its submission of a plan to regain compliance with respect to the Nasdaq Listing Rule, and the timing thereof. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to, uncertainties about the timing of the Company's submission of a compliance plan, Nasdaq's acceptance of any such plan, the duration of any extension that may be granted by Nasdaq, the potential inability to meet Nasdaq's requirements, the Company's preparation of the Quarterly Report on Form 10-Q for the period ended March 31, 2025 and the related financial statements, the possibility of additional delays in the filing of the Quarterly Report on Form 10-Q for the period ended March 31, 2025, and the other risks and uncertainties described in the Company's SEC reports and under the heading 'Risk Factors' in its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, which are available at These forward-looking statements speak only as of the date of this press release. Except as required by law, the Company does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release. Contact Information Andrew Sims, CFO Plus Therapeutics, Inc. 737-255-7194ir@
